Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 20/20 | 0.71 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981903 | 0.83 | TRPV1 (1.00) | TRPV1CDK8CLK4 | |
| SCHEMBL2319982 | 0.81 | TRPV1 (0.68) | TRPV1CYP3A4 | |
| SCHEMBL2319927 | 0.81 | TRPV1 (0.69) | TRPV1CYP3A4 | |
| SCHEMBL16494784 | 0.81 | TRPV1 (0.69) | TRPV1CDK8CLK4 | |
| SCHEMBL1984562 | 0.80 | TRPV1 (0.67) | TRPV1CDK8CLK4 | |
| SCHEMBL1981527 | 0.76 | TRPV1 (1.00) | TRPV1CDK8CLK4 | |
| SCHEMBL1979817 | 0.75 | TRPV1 (0.69) | TRPV1CYP3A4 | |
| SCHEMBL1981386 | 0.75 | TRPV1 (0.71) | TRPV1CYP3A4 | |
| SCHEMBL2315614 | 0.75 | TRPV1 (0.71) | TRPV1CYP3A4 | |
| SCHEMBL1979979 | 0.74 | TRPV1 (0.69) | TRPV1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| EP-2352727-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | claimed |
| EP-2352726-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | claimed |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| US-7812019-B2 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | claimed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | claimed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | claimed |
| WO-2010045402-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | claimed |
| WO-2010045401-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | claimed |
| EP-1844038-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006065484-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | claimed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | claimed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8440691-B2 | Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2527339-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | Abbott Laboratories (US) | 2012-11-28 | — | — | EP | disclosed |
| WO-2010045401-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-1844038-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006065484-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | CACNA1E, CACNA1D, CACNA1S | TRPV1 24/4885CDK8 2308/4885CLK4 3002/4885 |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CDK8 1270/4885CLK4 3639/4885 |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | CACNA1E, CACNA1D, CACNA1S | TRPV1 24/4885CDK8 2308/4885CLK4 3002/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885CDK8 1256/4885CLK4 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.